Impella

Type: Product
Name: Impella
First reported Jul 25 2014 - Updated Jul 26 2014 - 1 reports

US Federal Business Opportunity: Department of the Air Force: Impella Pump

Agency: Department of the Air ForceOffice: Air Education and Training Command Location: Keesler AFB, 81st Contracting SquadronDate you need to respond by: 29-July-2014Solicitation Number: FA3010-14-T-0052 Naics code: 334510 Computer and Electronic Product ... [Published ITbriefing - Jul 25 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

ABIOMED Makes a Move: Up 2.8%...

One of today's stocks on the move is ABIOMED (NASDAQ:ABMD), up 2.8% to $25.99. The Dow Jones Industrial Average is now trading 0.3% higher to 17,110 and the S&P is trading 0.5% higher to 1,985.Abiomed, Inc. provides medical devices in circulatory support ... [Published Financial News Network online - Jul 22 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

ARGEN X : Forbion Announces Closing of Initial Public Offering of Portfolio Company arGEN-X

By a News Reporter-Staff News Editor at Biotech Week -- Forbion Capital Partners , the leading Dutch Venture Capital firm investing in world-class healthcare technologies, is proud to announce that its portfolio company arGEN-X N.V. (arGEN-X or the company), ... [Published 4 Traders - Jul 16 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 2 reports

Forbion Capital Partners’ arGEN-X completes IPO

Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners ‘ portfolio company. PRESS RELEASE Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare ... [Published PE Hub Blog - Jul 09 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Abiomed announces acquisition of ECP

Abiomed has announced the acquisition of Germany-based medical device company ECP Entwicklungsgesellschaft mbH to broaden and strengthen existing intellectual property and product platform.Currently, ECP is developing a percutaneous, expandable catheter ... [Published Medical Devices Business Review - Jul 07 2014]
First reported Jul 01 2014 - Updated Jul 02 2014 - 5 reports

ABIOMED Acquires Germany's Medical Device Maker

ABIOMED Inc. ( ABMD ) revealed that it has acquired Berlin, Germany-based medical device maker Entwicklungsgesellschaft mbH or ECP. The acquisition is in line with its strategy to provide percutaneous hemodynamic support for minimally invasive procedures ... [Published Yahoo! Finance - Jul 02 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

US Federal Business Opportunity: Department of Veterans Affairs: J--Impella AIC Equipment PM Period of Performance: 7/1/14-6/30/15

Agency: Department of Veterans AffairsOffice: Seattle VAMC Location: Department of Veterans Affairs Puget Sound Health Care SystemDate you need to respond by:Solicitation Number: VA26014AP3714 Naics code: 334510 Computer and Electronic Product Manuf ... [Published ITbriefing - Jun 26 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Oxford Bioscience-backed Mitralign Raises $8 Million

According to an SEC filing, Mitralign Inc. has raised $8 million via sale of shares to 12 investors.The company, according to Crunchbase, has previously received $42 million from two rounds, including $35 million in Series D funding and $7 million in ... [Published Citybizlist - Jun 26 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Massapequa Schoolteacher Saved from Rare Heart Virus at St. Francis Hospital

“Please don’t let me die,” said Enzamaria Grimaudo, of Massapequa, before going into cardiac arrest. The 30-year-old schoolteacher clutched at a nurse as she began to turn blue. “Don’t worry,” the nurse said. “We won’t.”For the next four hours, doctors ... [Published Massapequa Patch - Jun 23 2014]
First reported Feb 20 2014 - Updated Feb 20 2014 - 1 reports

Forbion Announces Closing of Public Offering of Portfolio Company Argos Therapeutics

Forbion portfolio company developing novel cancer immunotherapy , based on Nobel Prize-winning scienceNaarden, The Netherlands – February 20 2014 – Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, ... [Published BioPortfolio - Feb 20 2014]
First reported Feb 13 2014 - Updated Feb 13 2014 - 1 reports

Forbion Capital-backed uniQure completes IPO

Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ... [Published PE Hub Blog - Feb 13 2014]

Quotes

Tim Van Hauwermeiren , CEO of arGEN-X, said: "The funds that we have raised through our successful IPO from investors in Europe and the US will enable arGEN-X to advance the clinical development of our differentiated therapeutic antibody candidates, ARGX-110, ARGX-111 and ARGX-113 in orphan diseases. This strategy is designed to yield clinical data demonstrating their therapeutic utility for treating cancer and severe autoimmune diseases, and this data will be leveraged to partner these therapeutic antibodies for development and commercialization across a number of major indications in these areas. The funds will also allow us to further develop and enhance our SIMPLE Antibody™ platform and suite of complementary antibody technologies on which our pipeline of differentiated therapeutic antibodies has been created. We believe that this approach will allow arGEN-X to become an important player in the fast growing therapeutic antibody market and to generate significant value for its shareholders in a timely and efficient manner."
"As the established leader in percutaneous heart pumps with deep relationships in cardiology, existing regulatory approvals, extensive IP, a solid pipeline and strong cash balance, this acquisition further strengthens our position as the long-term innovator and leader in the field of temporary ventricular assist devices" chairman, president & CEO Michael Minogue said in prepared remarks
NEXT ARTICLE More From BioPortfolio on "Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics"

More Content

All (21) | News (14) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 25 2014]
ABIOMED Makes a Move: Up 2.8%... [Published Financial News Network online - Jul 22 2014]
ARGEN X : Forbion Announces Closing of Initial ... [Published 4 Traders - Jul 16 2014]
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Forbion Announces Closing of Initial Public Off... [Published CNBC - Jul 09 2014]
Abiomed announces acquisition of ECP [Published Medical Devices Business Review - Jul 07 2014]
ABIOMED Acquires Germany's Medical Device Maker [Published Yahoo! Finance - Jul 02 2014]
Danvers heart device firm Abiomed acquires two ... [Published Boston Business Journal - Jul 02 2014]
Abiomed acquires German heart pump maker ECP [Published MassDevice - Jul 02 2014]
Abiomed Inc announces acquisition of ECP to bro... [Published Reuters - Jul 01 2014]
Abiomed Buys Germany-based ECP [Published RTTNews.com - Jul 01 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jun 26 2014]
Oxford Bioscience-backed Mitralign Raises $8 Mi... [Published Citybizlist - Jun 26 2014]
Massapequa Schoolteacher Saved from Rare Heart ... [Published Massapequa Patch - Jun 23 2014]
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
Impella Maintains Existing Diagnosis Related Gr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Abiomed Completes Patient Enrollment in RECOVER... [Published GlobeNewswire: Acquisitions News - Mar 20 2014]
Forbion Announces Closing of Public Offering of... [Published BioPortfolio - Feb 20 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners ‘ portfolio company. PRESS RELEASE Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Press Releases

sort by: Date | Relevance
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
Impella Maintains Existing Diagnosis Related Gr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Abiomed Completes Patient Enrollment in RECOVER... [Published GlobeNewswire: Acquisitions News - Mar 20 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.